Glaukos (GKOS) has drawn investor interest after its shares closed at US$184.89, following a period of strong multi year total returns. The move has brought renewed attention to how the ophthalmic specialist is currently valued.

Over the past month Glaukos has recorded a 20.39% 1 month share price return and a 60.82% 3 month share price return, while the 1 year total shareholder return of 101.96% and 5 year total shareholder return of 223.86% point to momentum that has built over several years.

If Glaukos has you thinking about what else is gaining traction in medical technology, it could be worth scanning 41 healthcare AI stocks

After a sharp run that has lifted Glaukos to US$184.89, some investors will be tempted to wait for a pullback. Others may see the strength as confirmation. So what does the current valuation actually suggest?

Most Popular Narrative: 6% Undervalued

Glaukos is trading at $184.89, while the most followed narrative places fair value closer to $196. This gap is rooted in some punchy growth assumptions.

Strong ongoing adoption and utilization of iDose TR, a first of its kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies, a substantial long term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi year revenue and market expansion.

Want to see what is behind that valuation jump for Glaukos? The narrative references rapid revenue expansion, rising margins and a rich future earnings multiple. Investors may be curious which exact mix of growth and profitability is used to back into that fair value.

Result: Fair Value of $196.46 (UNDERVALUED)

However, Glaukos investors should also factor in risks such as tighter reimbursement for ophthalmic procedures and potential setbacks or delays in clinical trials and product approvals.

Another View: What Multiples Say About Glaukos

The analyst narrative and fair value of $196.46 present Glaukos as modestly undervalued. However, the current P/S ratio of 17.8x is far above the US Medical Equipment industry at 2.9x and peers at 4.2x, and also above a fair ratio of 8.9x. That gap points to valuation risk if growth stumbles.

For a closer look at how this rich sales multiple compares and what it could mean if the market moves toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment running high around Glaukos, it helps to pressure test the story against the underlying data and your own risk tolerance. To see what optimism in the market is focusing on right now, take a closer look at the 2 key rewards

Looking for more investment ideas beyond Glaukos?

If Glaukos has sharpened your focus on opportunities in healthcare, do not stop there. Use data driven stock lists to spot other ideas before the crowd.

• Target resilient cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (50 results) that can better withstand shocks and keep funding their growth plans.
• Hunt for quality at a potential discount by scanning the 48 high quality undervalued stocks that highlight businesses where fundamentals and price do not fully line up.
• Spot potential future leaders early by checking the screener containing 17 high quality undiscovered gems that flag under followed stocks with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.